Loading…
Loading…
MRUS (Merus N.V.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
MRUS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MRUS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MRUS and 80,000+ other tickers.
See exactly how MRUS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MRUS and 80,000+ other tickers.
Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158…
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track to Initiate Phase 2 Proof-of-Concept Study of ATH-1105 in ALS patients in 2H 2026 Recent Events Include Three Appointments to Board of Directors and Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc.(NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended March 31, 2026, and provided recent pipeline and business updates.
YLÖJÄRVI, Finland--(BUSINESS WIRE)--Merus Power Oyj has signed a battery energy storage deal worth approximately 13 million euros with Neve Oy.
Federated Hermes Inc. lessened its position in Merus N.V. (NASDAQ: MRUS) by 18.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,249,162 shares of the biotechnology company's stock after selling 279,425 shares during the period. Federated Hermes Inc. owned
Merus N.V. (NASDAQ: MRUS - Get Free Report) has earned an average recommendation of "Hold" from the eighteen brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have issued a buy rating on the company. The average
Stock News BYD overtakes Tesla in EV sales: Tesla (TSLA) delivered 1.64M vehicles in 2025, ceding the global EV crown to China's BYD (HKG:1211) with 2.26M sold,